Ortho Clinical Diagnostics Holdings plc
Ortho Clinical Diagnostics Holdings plc (OCDX): 5 pipeline candidates · ~370 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
370.2 months
D/E 6.48 · 2% dilution
Lead: Approved
5 candidates
N/A
N/A
A transparent, data-derived signal for Ortho Clinical Diagnostics Holdings plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$281.1M
Quarterly Burn
$4.0M
Runway
370.2 mo
Revenue
$500.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
Frequently asked questions
How many drug candidates are in Ortho Clinical Diagnostics Holdings plc's pipeline?
Ortho Clinical Diagnostics Holdings plc (OCDX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Ortho Clinical Diagnostics Holdings plc's lead drug candidate?
Ortho Clinical Diagnostics Holdings plc's most advanced tracked candidate is amersham afp (Approved) for Immunology.
What is Ortho Clinical Diagnostics Holdings plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Ortho Clinical Diagnostics Holdings plc has approximately 370.2 months of cash runway.
Who is the CEO of Ortho Clinical Diagnostics Holdings plc?
Christopher Smith is the chief executive officer of Ortho Clinical Diagnostics Holdings plc (OCDX).
Get the full picture on Ortho Clinical Diagnostics Holdings plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.